{"id":"eribulin-mesylate-injection","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Neutropenia"},{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"40-60","effect":"Anemia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"30-40","effect":"Nausea"},{"rate":"20-30","effect":"Alopecia"},{"rate":"15-25","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1683544","moleculeType":"Small molecule","molecularWeight":"826.01"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eribulin mesylate is a non-taxane microtubule inhibitor that works by binding to the plus end of microtubules and inhibiting their growth phase while allowing shortening to continue, resulting in net loss of microtubule mass. This disruption of microtubule dynamics leads to G2/M cell cycle arrest and triggers apoptosis in rapidly dividing cancer cells. Unlike taxanes, eribulin does not stabilize microtubules but rather destabilizes them through a unique mechanism of action.","oneSentence":"Eribulin mesylate is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:19.535Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Liposarcoma"},{"name":"Other solid tumors (in clinical development)"}]},"trialDetails":[{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT07494448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07-01","conditions":"HER 2 Positive Advanced Breast Cancer, Breast Cancer","enrollment":24},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07078604","phase":"PHASE2","title":"A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-11","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":20},{"nctId":"NCT04639986","phase":"PHASE3","title":"Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2020-11-23","conditions":"Metastatic Breast Cancer","enrollment":331},{"nctId":"NCT07047365","phase":"PHASE3","title":"TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-07-25","conditions":"HER2-positive Advanced Breast Cancer","enrollment":416},{"nctId":"NCT06072612","phase":"PHASE3","title":"Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"BriaCell Therapeutics Corporation","startDate":"2023-12-05","conditions":"Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm","enrollment":404},{"nctId":"NCT05347134","phase":"PHASE3","title":"SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2022-06-10","conditions":"Triple Negative Breast Cancer","enrollment":254},{"nctId":"NCT06081959","phase":"PHASE3","title":"Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2023-10-31","conditions":"Metastatic Breast Cancer","enrollment":376},{"nctId":"NCT07255612","phase":"PHASE2","title":"Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-11-04","conditions":"Breast Cancer","enrollment":29},{"nctId":"NCT07205185","phase":"PHASE2","title":"A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-01","conditions":"Soft Tissue Sarcoma (STS)","enrollment":46},{"nctId":"NCT06732323","phase":"PHASE3","title":"A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-04","conditions":"Triple-Negative Breast Cancer (TNBC)","enrollment":504},{"nctId":"NCT06079983","phase":"PHASE3","title":"JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2023-12-01","conditions":"Breast Cancer","enrollment":400},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06383767","phase":"PHASE3","title":"A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-07-11","conditions":"Metastatic Breast Cancer","enrollment":378},{"nctId":"NCT03222856","phase":"PHASE2","title":"Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes","status":"COMPLETED","sponsor":"MedSIR","startDate":"2017-12-14","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT06775236","phase":"PHASE1, PHASE2","title":"Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-03-20","conditions":"Advanced Solid Tumors, Breast Cancer","enrollment":410},{"nctId":"NCT06143553","phase":"PHASE3","title":"Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Shanghai Yizhong Pharmaceutical Co., Ltd.","startDate":"2023-09-25","conditions":"Metastatic Breast Cancer (MBC)","enrollment":168},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT03901339","phase":"PHASE3","title":"Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2019-05-08","conditions":"Metastatic Breast Cancer","enrollment":543},{"nctId":"NCT05420779","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations","status":"RECRUITING","sponsor":"Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.","startDate":"2022-06-30","conditions":"Breast Cancer Metastatic","enrollment":125},{"nctId":"NCT06202261","phase":"PHASE1, PHASE2","title":"A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-04-13","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies","enrollment":154},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT03786094","phase":"PHASE3","title":"Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Spexis AG","startDate":"2019-05-30","conditions":"Metastatic Breast Cancer, Locally Recurrent Breast Cancer","enrollment":432},{"nctId":"NCT05953909","phase":"","title":"A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2023-02-01","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT05814354","phase":"PHASE3","title":"SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-06-30","conditions":"Breast Cancer","enrollment":530},{"nctId":"NCT05945368","phase":"PHASE2","title":"A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-02-25","conditions":"HER2-positive Breast Cancer","enrollment":78},{"nctId":"NCT05033769","phase":"PHASE4","title":"Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Institut fuer Frauengesundheit","startDate":"2021-03-11","conditions":"Breast Cancer Female, Neoplasm, Breast, Breast Cancer Metastatic","enrollment":82},{"nctId":"NCT04303741","phase":"PHASE2","title":"A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2020-03-25","conditions":"Breast Cancer","enrollment":46},{"nctId":"NCT05206656","phase":"PHASE2","title":"Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Hunan Cancer Hospital","startDate":"2020-10-09","conditions":"Metastatic Breast Cancer","enrollment":80},{"nctId":"NCT05621434","phase":"PHASE2","title":"A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2022-12-10","conditions":"HER2-positive Recurrent/Metastatic Breast Cancer","enrollment":63},{"nctId":"NCT03810976","phase":"PHASE2","title":"A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2018-03-27","conditions":"Sarcoma","enrollment":37},{"nctId":"NCT02574455","phase":"PHASE3","title":"Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-11-07","conditions":"Breast Cancer","enrollment":529},{"nctId":"NCT05402722","phase":"PHASE2","title":"Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2022-01-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":30},{"nctId":"NCT05263882","phase":"PHASE2","title":"Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-03","conditions":"HER2-negative Breast Cancer","enrollment":58},{"nctId":"NCT03056599","phase":"PHASE1","title":"Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"Presage Biosciences","startDate":"2016-12-15","conditions":"Soft Tissue Sarcoma Adult","enrollment":23},{"nctId":"NCT03795012","phase":"PHASE2","title":"Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients","status":"TERMINATED","sponsor":"MedSIR","startDate":"2019-04-30","conditions":"Breast Cancer","enrollment":22},{"nctId":"NCT03058406","phase":"","title":"A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2016-03-01","conditions":"Sarcoma, Soft Tissue","enrollment":256},{"nctId":"NCT02441764","phase":"","title":"Halaven Post-Marketing Surveillance (PMS)","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2013-03","conditions":"Breast Cancer","enrollment":3000},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT02481050","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2015-06-16","conditions":"Breast Cancer","enrollment":58},{"nctId":"NCT02225470","phase":"PHASE3","title":"Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2013-09-26","conditions":"HER2-Negative Breast Cancer, Triple Negative Breast Cancer, Breast Cancer","enrollment":530},{"nctId":"NCT00706095","phase":"PHASE1","title":"Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-02","conditions":"Cancer","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Halaven"],"phase":"phase_3","status":"active","brandName":"Eribulin mesylate injection","genericName":"Eribulin mesylate injection","companyName":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","companyId":"jiangsu-alphamab-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eribulin mesylate is a microtubule dynamics inhibitor that binds to tubulin and suppresses microtubule growth, leading to cell cycle arrest and apoptosis in cancer cells. Used for Metastatic breast cancer, Liposarcoma, Other solid tumors (in clinical development).","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2011-03-17T00:00:00.000Z","mah":"Eisai GmbH","brand_name_local":"Halaven","application_number":"EMEA/H/C/002084"}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}